Journal article
BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for lynch syndrome
CW Toon, MD Walsh, A Chou, D Capper, A Clarkson, L Sioson, S Clarke, S Mead, RJ Walters, M Clendenning, C Rosty, JP Young, AK Win, JL Hopper, A Crook, A von Deimling, MA Jenkins, DD Buchanan, AJ Gill
American Journal of Surgical Pathology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2013
Abstract
BRAFV600E mutation in microsatellite-unstable (MSI) colorectal carcinomas (CRCs) virtually excludes Lynch syndrome (LS). In microsatellite-stable (MSS) CRCs it predicts poor prognosis. We propose a universal CRC LS screening algorithm using concurrent reflex immunohistochemistry (IHC) for BRAFV600E and mismatch-repair (MMR) proteins. We compared BRAFV600E IHC with multiplex polymerase chain reaction (PCR) and matrix-assisted laser desorption/ionization-time of flight mass spectrometry in 216 consecutive CRCs from 2011. Discordant cases were resolved with real-time PCR. BRAFV600E IHC was performed on 51 CRCs from the Australasian Colorectal Cancer Family Registry (ACCFR), which were fully cha..
View full abstractRelated Projects (1)
Grants
Awarded by National Cancer Institute
Funding Acknowledgements
Funded by the National Cancer Institute, National Institutes of Health under RFA #CA-95-011 and through cooperative agreements with members of the Colon-Cancer-Family-Registry and Principal Investigators of Australasian-Colorectal-Cancer-Family Registry (U01CA097735). Under a licensing agreement between Ventana Medical Systems Inc., Tucson, AZ, and the German Cancer Research Center, D. C. and A. v. D. are entitled to a share of royalties received by the German Cancer Research Center on the sales of VE1 antibody. The terms of this arrangement are being managed by the German Cancer Research Center in accordance with its conflict of interest policies. S. M. is a paid consultant for Roche Molecular Advisory Committee. For the remaining authors none were declared.